# Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)

> **NCT05710224** · PHASE2 · COMPLETED · sponsor: **Butantan Institute** · enrollment: 1364 (actual)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** V181
- **BIOLOGICAL:** Butantan - DV

## Key facts

- **NCT ID:** NCT05710224
- **Lead sponsor:** Butantan Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-15
- **Primary completion:** 2024-01-22
- **Final completion:** 2024-12-12
- **Target enrollment:** 1364 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05710224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05710224, "Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05710224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*